Track topics on Twitter Track topics that are important to you
Locus Biosciences, developer of a next-generation CRISPR /Cas platform for precision antimicrobials, has closed $19 million in Series A funding designed to fund the company through filing its first Investigational New Drug (IND), as well as a subsequent first-in-human trial. A spinout of North Carolina State University (NCSU) founded in 2015, Locus Biosciences designs and creates novel CRISPR RNAs or “smart bombs” designed to kill antibiotic-resistant “superbugs” by irreversibly destroying the bacterial DNA. Locus says it is the only company that uses CRISPR/Cas3 to kill targeted pathogens, such as Clostridium difficile, Pseudomonas aeruginosa , and Enterobacteriaceae—rather than with Cas9 as used by Paris-based Eligo Bioscience, which on September 26 said it closed on $20 million in Series A financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. As a result, Locus steers clear of the bitter legal battle ...NEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...